2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. SGK
  5. SGK1 Isoform

SGK1

 

SGK1 Related Products (13):

Cat. No. Product Name Effect Purity
  • HY-15192
    GSK 650394
    		Inhibitor 99.76%
    GSK 650394 is a novel SGK inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication.
  • HY-15193
    EMD638683
    		Inhibitor 99.94%
    EMD638683 is an orally active SGK1 inhibitor with an IC50 of 3 μM. EMD638683 exhibits strong inhibition against SGK1, moderate inhibition against SGK2 and SGK3, and shows excellent selectivity for other AGC kinase family members. EMD638683 has antihypertensive activity by inhibiting SGK1, and independently of the blood pressure-lowering effect, it effectively prevents heart inflammation and fibrosis caused by hypertension by inhibiting the cardiac NLRP3 inflammation body/ IL-1β axis. EMD638683 promotes apoptosis of colon cancer cells and sensitizes radiotherapy. EMD638683 (S-Form) can be used in research related to hypertension, hypertensive heart damage, and colon cancer.
  • HY-18607
    SGK1-IN-1
    		Inhibitor 99.57%
    SGK1-IN-1 is a highly active and selective inhibitor of SGK-1, with an IC50 of 1 nM.
  • HY-167832
    PT109
    		Inhibitor 99.20%
    PT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease.
  • HY-135893
    SGK1-IN-2
    		Inhibitor 98.36%
    SGK1-IN-2 (Compound 14h) is a selective, ATP-competitive SGK1 inhibitor, with an IC50 of 0.005 μM at 10 μM ATP and an IC50 of 0.025 μM at 500 μM ATP. SGK1-IN-2 can be used in studies of cancer, hypertension and diabetes.
  • HY-185412
    SGK1-IN-9
    		Inhibitor
    SGK1-IN-9 (Compound 1) is a SGK1 inhibitor. SGK1-IN-9 can be used in cancer research.
  • HY-15193B
    EMD638683 (S-Form)
    		Inhibitor 99.95%
    EMD638683 (S-Form) (Compound 1a), the S-enantiomer of EMD638683 (HY-15193), is a SGK1 inhibitor with an IC50 value > 300 nM. EMD638683 is an orally active SGK1 inhibitor with an IC50 of 3 μM. EMD638683 exhibits strong inhibition against SGK1, moderate inhibition against SGK2 and SGK3, and shows excellent selectivity for other AGC kinase family members. EMD638683 has antihypertensive activity by inhibiting SGK1, and independently of the blood pressure-lowering effect, it effectively prevents heart inflammation and fibrosis caused by hypertension by inhibiting the cardiac NLRP3 inflammation body/ IL-1β axis. EMD638683 promotes apoptosis of colon cancer cells and sensitizes radiotherapy. EMD638683 (S-Form) can be used in research related to hypertension, hypertensive heart damage, and colon cancer.
  • HY-142686A
    SGK1-IN-3 hydrochloride
    		Inhibitor
    SGK1-IN-3 hydrochloride (Compound 3a) is an ATP-competitive SGK1 inhibitor with an IC50 of <1 nM against hSGK1. SGK1-IN-3 hydrochloride blocks the activity of CDK family members. SGK1-IN-3 hydrochloride serves as a P-glycoprotein substrate. SGK1-IN-3 can be used for the research of osteoarthritis.
  • HY-15193A
    EMD638683 (R-Form)
    		Inhibitor 99.86%
    EMD638683 R-Form is the R-form of EMD638683 (HY-15193). EMD638683 is a highly selective SGK1 inhibitor.
  • HY-142686
    SGK1-IN-3
    		Inhibitor
    SGK1-IN-3 (Compound 3a) is an ATP-competitive SGK1 inhibitor with an IC50 of <1 nM against hSGK1. SGK1-IN-3 blocks the activity of CDK family members. SGK1-IN-3 is a P-glycoprotein substrate. SGK1-IN-3 can be used for research on osteoarthritis.
  • HY-128221
    SGK1-IN-5
    		Inhibitor
    SGK1-IN-5 is a SGK1 inhibitor with an IC50 of 0.003 μM. SGK1-IN-5 can be used for the research of osteoarthritis, rheumatism.
  • HY-170933
    SGK1-IN-6
    		Inhibitor
    SGK1-IN-6 is a selective SGK1 inhibitor with an IC50 of 0.39 μM, showing selectivity over SGK2/3. SGK1-IN-6 inhibits cancer cell migration and invasion, improves SGK1 protein thermal stability. SGK1-IN-6 decreases SGK1 protein levels in tumor tissues, suppresses tumor growth in mouse xenograft models. SGK1-IN-6 can be used for the research of prostate cancer.
  • HY-176823
    PROTAC SGK3 degrader-2
    		Degrader
    PROTAC SGK3 degrader-2 is the cis epimer of PROTAC SGK3 degrader-1 (SGK3-PROTAC1) (HY-125878), with a cis hydroxyl group in its VH032 moiety, which is incapable of binding to the VHL E3 ligase. PROTAC SGK3 degrader-2 exhibits inhibitory activity against SGK3, SGK1, and S6K1 with IC50 values of 0.6 μM, 1.4 μM, and 1.7 μM, respectively, but shows no SGK3 degradation efficiency. PROTAC SGK3 degrader-2 can be used as a control compound to study the specific effects of SGK3-PROTAC1-mediated SGK3 degradation. (Pink: SGK3 ligand (HY-167701), Blue: VHL Ligand (HY-120217A), Black: Linker (HY-130618), SGK3 ligand-linker conjugate (HY-176824)).